SGRY — Surgery Partners, Inc.
Is SGRY overbought or oversold? Here is the current MarketMoodz read.
Surgery Partners, Inc. (SGRY) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Care Facilities) last closed at $26.79. The rating moved from Overbought to Neutral on November 17, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$26.79
- Last changeMoved from Overbought to Neutral on November 17, 2026
- SectorHealthcare
- IndustryMedical Care Facilities
AI analysis
Surgery Partners, Inc. (SGRY) sits in a favorable secular niche as procedures shift toward outpatient settings and surgical robotics expand the addressable market. The company can grow via new ASC openings and targeted acquisitions while extracting operational leverage from improved case mix and payer contracting. Near-term sentiment is cautious but neutral newsflow has not introduced material downside. Key vulnerabilities include reimbursement/regulatory changes, competition from hospital systems, capex needs tied to robotics adoption, and labor/cost pressures that could compress margins. Overall scenarios range from steady volume-driven recovery and margin improvement if execution continues, to episodic earnings pressure if policy or utilization weakens.
Key factors
- Positioned in outpatient surgical services and ambulatory surgery centers (ASCs), benefiting from secular shift from inpatient to outpatient procedures
- Surgical robotics expansion increases addressable market and could drive procedure volume and higher-margin consumable revenue for facility partners
- Growth runway through greenfield development and M&A to expand footprint and specialty mix
- Operational leverage potential from case-mix optimization, payer contracting focus, and cost controls after recent integration cycles
- Neutral near-term market sentiment and a recent Form 8-K with no major negative surprise
Risks
- Reimbursement and regulatory risk, including potential Medicare/Medicare Advantage policy changes that could pressure outpatient payment levels or prior authorization processes
- Competition and consolidation from large health systems and competing ASC operators driving pricing and referral dynamics
- Capital intensity and balance-sheet pressure if rapid adoption of robotics and OR integration requires elevated capex or leasing costs
- Labor market pressures and staffing shortages that could increase operating costs or limit capacity utilization
- Execution and integration risk from acquisitions and new center openings, which could dilute near-term margins
- Macro downside that reduces elective procedure volumes in a risk-off environment
See today's live rating, score and targets
Members see the live hourly rating for SGRY — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.